Season's Savings | ₹5/mo for 3 months

₹199/month after first 3 months. Renews automatically. Terms apply.
AVBCC Value-Based Voices cover art

AVBCC Value-Based Voices

AVBCC Value-Based Voices

Written by: Rachael
Listen for free

About this listen

The Association for Value-Based Cancer Care’s (AVBCC) podcast series addresses the ever-evolving

landscape of value related to cancer care in the United States. Our goal is to foster informed dialogue, promote transparency, and empower all players to navigate the rapidly changing landscape of cancer care with clarity and confidence.

© 2026 AVBCC Value-Based Voices
Economics Management Management & Leadership
Episodes
  • Medicare Advantage, AI, MFN, China, and Consensus Building: Powerful Insights from HLC
    Oct 15 2026

    Value-Based Voices welcomes Maria Ghazal, JD, MA, President & CEO, Healthcare Leadership Council, for a dynamic conversation spanning Medicare Advantage, prior authorization reform, artificial intelligence, Most Favored Nation drug pricing, and the growing competitive pressure from China in biopharmaceutical innovation.

    During this conversation, hosted by Jayson Slotnik, JD, MPH, Partner at Health Policy Strategies, and AVBCC Board Member, Maria shares insights from HLC’s diverse membership of 60+ C-suite leaders and explains how consensus-driven policy can shape the future of value-based care.

    Together, Jayson and Maria explore:

    • The evolving landscape of Medicare Advantage

    • HLC’s newly released AI policy recommendations

    • The implications of Most Favored Nation drug pricing and why affordability and innovation must not be treated as competing goals

    • The rapid rise of China in biopharmaceutical development and AI-enabled healthcare—and what the U.S. must do to maintain leadership

    • How HLC builds consensus across one of the most diverse memberships in healthcare

    This episode offers a candid, cross-sector look at the policies, pressures, and opportunities that will define the next decade of value-based care.

    Listen and subscribe for more conversations shaping the future of oncology and value-based healthcare.

    #ValueBasedCare #MedicareAdvantage #HealthcarePolicy #AIinHealthcare #AI #Innovation #AVBCC #HLC #China #biopharma


    Resources:

    Association for Value-Based Cancer Care (AVBCC): https://avbcc.org/

    Healthcare Leadership Council (HLC): https://www.hlc.org/

    Medicare Advantage cost analysis & MedPAC rebuttal: https://www.hlc.org/news/hlc-leader-reacts-to-latest-medpac-report-to-congress-on-medicare-payment-policy/

    AI Federal Framework Preliminary Report: https://www.hlc.org/news/healthcare-sector-calls-for-unified-federal-framework-to-unlock-ais-full-potential-for-patients/

    Improving Seniors’ Timely Access to Care Act: https://www.congress.gov/bill/119th-congress/house-bill/3514

    CMS prior authorization reforms: https://www.cms.gov/initiatives/burden-reduction/overview/interoperability/policies-regulations/cms-interoperability-standards-prior-authorization-drugs-proposed-rule-cms-0062-p


    Connect with our Guests:

    Maria Ghazal, JD, MA: https://www.linkedin.com/in/maria-ghazal/

    Jayson Slotnik: https://www.linkedin.com/in/jayson-slotnik-3932305/

    Contact Value-Based Voices

    - Follow AVBCC on LinkedIn

    - View our podcast lineup

    - Contact us at info@avbcc.org

    Thanks for listening!

    Show More Show Less
    40 mins
  • Ted Slafsky on 340B's Triple Threat: CMS Cuts, the Rebate Model Fight & Contract Pharmacy in Court
    Nov 12 2026

    CMS has just finalized a cut to hospital payments for 340B drugs, from ASP+6% down to ASP-28%. The lawsuits are already on the way. Host Jayson Slotnik sits down with Ted Slafsky, Publisher and CEO of the 340B Report, to break down three fast-moving 340B fights: the new CMS reimbursement decision, the hospital lawsuit against HRSA's 340B rebate model (oral arguments November 18 in Portland, Maine), and the circuit split over state contract pharmacy laws now before the full Fourth Circuit. Ted also gives his predictions on how each case will turn out.

    Want to know if Ted's predictions come true? Subscribe to the 340B Report at https://340breport.com. Value-Based Voices listeners get 25% off with code AVBCC25.

    Resources
    • 340B Report: https://340breport.com
    • Inside 340B Report podcast (from the 340B Report team): https://340breport.com/podcasts/inside-340b-report-podcast/
    • Association for Value-Based Cancer Care: AVBCC.org

    Connect with Our Guests

    • Ted Slafsky, Publisher & CEO, 340B Report: https://www.linkedin.com/in/ted-slafsky-12859793
    • Jayson Slotnik, JD, MPH, Partner, Health Policy Strategies, Inc.: https://www.linkedin.com/in/jayson-slotnik-3932305/


    Contact Value-Based Voices

    - Follow AVBCC on LinkedIn

    - View our podcast lineup

    - Contact us at info@avbcc.org

    Thanks for listening!

    Show More Show Less
    49 mins
  • Who Gets Access? Understanding the New Reality of Cancer Drug Coverage
    Sep 29 2026

    Are oncology treatments losing their "special status" with payers?

    In this episode of Value-Based Voices, host Brian Reid, MS, Principal of Reid Strategic and author of the Cost Curve newsletter, sits down with James Chambers, PhD, MSc, MPharm, Professor at Tufts University School of Medicine and Director of the Specialty Drug Evidence and Coverage (SPEC) Database, to examine how payer coverage decisions are shaping access to cancer therapies in the United States.

    Drawing on nearly a decade of research, Dr. Chambers discusses the growing use of utilization management tools, including step therapy and clinical eligibility requirements, and explains why oncology, long considered one of the least restricted therapeutic areas, is seeing a noticeable increase in coverage limitations. The conversation explores payer variation, the impact of biosimilars and therapeutic competition, and the unique challenges associated with cell and gene therapies.

    Listeners will gain valuable insights into the complex balance between innovation, affordability, evidence, and patient access that continues to define the modern oncology landscape.

    #Oncology #DrugCoverage #CancerDrugs #cancer #PatientAccess #HealthcarePolicy

    Resources & Links
    • Specialty Drug Evidence and Coverage (SPEC) Database: https://cevr.tuftsmedicalcenter.org/databases/spec-database
    • Association for Value-Based Cancer Care (AVBCC): http://avbcc.org

    Connect with our Guests:
    Brian Reed: https://www.linkedin.com/in/brianbreid/
    James Chambers, PhD, MSc, MPharm: https://www.linkedin.com/in/james-chambers-8845752/

    Contact Value-Based Voices

    - Follow AVBCC on LinkedIn

    - View our podcast lineup

    - Contact us at info@avbcc.org

    Thanks for listening!

    Show More Show Less
    28 mins
adbl_web_anon_alc_button_suppression_t1
No reviews yet